Pablo Barreiro MD PhD, Regional Public Health Laboratory. Comunidad de Madrid. Infectious Diseases. Internal Medicine. Hospital General Universitario La Paz. Madrid, Spain. Department of Medical Specialties and Public Health. School of Medicine. Universidad Rey Juan Carlos, 28922 Madrid, Spain.
Rev Esp Quimioter. 2023 Nov;36 Suppl 1(Suppl 1):15-17. doi: 10.37201/req/s01.04.2023. Epub 2023 Nov 24.
Despite the fact that COVID is today not a life-threat for the general population, recipients of solid organ transplantation should be viewed as a high risk group for severe COVID. Repetitive doses of SARS-CoV-2 vaccine still fail to protect SOT recipients from infection, disease or even death caused by COVID. A more frequent need for medical care may initially place these patients at greater chances of SARS-CoV-2 infection. Immunosuppression after engrafting and underlying medical conditions that led to the practice of SOT contribute to more risk of severe infection. Immunosuppression also blunts the intensity of humoral and cellular responses after vaccination, even when several booster doses have been administered. Still, vaccination is the best strategy to prevent a fatal outcome in case of SARS-CoV-2 infection, with a particular reduction in mortality. SOT recipients should be considered a high-risk population that need yearly SARS-CoV-2 vaccination.
尽管 COVID 如今对普通人群来说已不构成生命威胁,但实体器官移植受者应被视为 COVID 重症的高危人群。重复接种 SARS-CoV-2 疫苗仍然不能保护 SOT 受者免受 COVID 感染、疾病甚至死亡的影响。更频繁的医疗需求可能最初会使这些患者面临更大的感染 SARS-CoV-2 的风险。移植后免疫抑制和导致 SOT 实践的基础医学状况导致更严重感染的风险增加。免疫抑制还会削弱接种疫苗后体液和细胞反应的强度,即使已经接种了几剂加强针。尽管如此,接种疫苗仍然是预防 SARS-CoV-2 感染导致致命后果的最佳策略,尤其是可以降低死亡率。SOT 受者应被视为高危人群,需要每年接种 SARS-CoV-2 疫苗。